SEC Form SC 13G/A filed by BridgeBio Pharma Inc. (Amendment)
$BBIO
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/3/2026 | $104.00 | Buy | Canaccord Genuity |
| 5/26/2026 | Outperform → Mkt Perform | Raymond James | |
| 5/19/2026 | $82.00 | Neutral | Citigroup |
| 4/9/2026 | $100.00 | Outperform | RBC Capital Mkts |
| 3/10/2026 | Outperform | William Blair | |
| 1/28/2026 | $157.00 | Overweight | Barclays |
| 1/6/2026 | $96.00 | Overweight | Morgan Stanley |
| 12/11/2025 | $94.00 | Outperform | Bernstein |
Canaccord Genuity initiated coverage of BridgeBio Pharma with a rating of Buy and set a new price target of $104.00
Raymond James downgraded BridgeBio Pharma from Outperform to Mkt Perform
Citigroup initiated coverage of BridgeBio Pharma with a rating of Neutral and set a new price target of $82.00
- Accepted for Priority Review with PDUFA target action date of November 27, 2026, and poised to launch upon approval; being granted Priority Review by the FDA reiterates the serious unmet need for treatment options for the LGMD2I/R9 community - If approved, BBP-418 would be the first and only therapy for individuals living with LGMD2I/R9 and would represent the first approved treatment for any form of LGMD - BBP-418 demonstrated strong, consistent efficacy across all prespecified subgroups with treated individuals improving on every key endpoint while placebo recipients declined, reflecting both the natural progression of this devastating disease and the meaningful potential impact for th
ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.USANewsGroup.com News CommentaryVANCOUVER, BC, May 12, 2026 /CNW/ -- Cardiovascular disease is about to become the most expensive problem in American medicine. The American Heart Association fired a warning shot in late April: U.S. heart disease costs are on pace to quadruple by 2050, and total national healthcare spending is already closing in on $5 trillion a year[1]. That kind of structural pressure is forcing hospitals to rethink how they diagnose and treat cardiac patients, and the money is following. The global AI cardiology market, valued at $2.78 billion this year, is projected to reach over $14 billion by 2034 as health systems race to
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1 - All pre-specified primary and key secondary efficacy endpoints were met in the Phase 3 CALIBRATE trial; 76% of participants administered encaleret achieved both serum and urine calcium within the respective target ranges at Week 24 compared to 4% when on conventional therapy at Week 4 (p<0.0001) - Encaleret may be eligible for priority review; BridgeBio anticipates U.S. launch in early 2027 - If approved, encaleret could be the first approved therapy specifically indicated for individuals living with
SCHEDULE 13G - BridgeBio Pharma, Inc. (0001743881) (Subject)
8-K - BridgeBio Pharma, Inc. (0001743881) (Filer)
144 - BridgeBio Pharma, Inc. (0001743881) (Subject)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4/A - BridgeBio Pharma, Inc. (0001743881) (Issuer)
4 - BridgeBio Pharma, Inc. (0001743881) (Issuer)
Submission status for BRIDGEBIO PHARMA INC's drug ATTRUBY (ORIG-1) with active ingredient ACORAMIDIS has changed to 'Approval' on 11/22/2024. Application Category: NDA, Application Number: 216540, Application Classification: Type 1 - New Molecular Entity
$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial momentumContinued broad uptake among all patient types and HCP segments with particularly strong and growing demand in treatment naïve patients; global launch gaining traction with recent Brazil approvalReal-world evidence reinforces the differentiation demonstrated in trial data. Analysis recently released on medRxiv.org shows Attruby reduces diuretic intensification by 43% compared to tafamidis; in addition, an independent real world evidence study presented at SCAI also revealed statistically s
PALO ALTO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that it will release its first quarter 2026 financial results and business update after the market closes on Thursday, May 7, 2026. BridgeBio will host a conference call to discuss the financial results and program updates at 4:30 pm ET the same day. To access the live webcast of BridgeBio's presentation, please visit the "Events & Presentations" page within the Investors section of the BridgeBio website at investor.bridgebio.com/events-and-presentations/. A replay of t
$154.2 million in total fourth quarter revenues, net, and $502.1 million in full year revenues, net, primarily comprised of net product revenue of $146.0 million and $362.4 million, respectivelyBridgeBio reported three positive Phase 3 trial readouts in just over three months, a demonstration of its unique model for sustainable drug development as described in a recent peer-reviewed manuscriptAttruby continues to demonstrate clinical differentiation as a first-choice therapy in ATTR-CM with the greatest TTR stabilization on the market (≥90%) and the most rapid benefit on clinical outcomes observed within 1 month, with 7,804 unique patient prescriptions written by 1,856 unique prescribers as
SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
SC 13D/A - BridgeBio Pharma, Inc. (0001743881) (Subject)
PALO ALTO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-stage biopharmaceutical company focused on genetic diseases, announced that Thomas Trimarchi, Ph.D., has been appointed President and Chief Operating Officer (COO) of the company. Dr. Trimarchi will assume his new responsibilities effective immediately and will continue to report directly to CEO and founder, Neil Kumar, Ph.D. In this newly created position, Dr. Trimarchi will be responsible for driving operational excellence, strategic planning, and overall business success at BridgeBio. He will lead cross-functional activities to develop a centralized ope
The oversubscribed financing was led by Cormorant Asset Management and co-led by Omega Funds with participation from affiliates of Deerfield Management, GV (Google Ventures), EcoR1 Capital, Wellington Management, Enavate Sciences, Surveyor Capital (a Citadel company), Aisling Capital, Casdin Capital, and Longwood FundThis capital raise provides BBOT with runway to achieve significant clinical inflection points over the next 18-24 months as it progresses multiple assets into the clinic to treat patients with a wide variety of RAS and PI3Kα pathway malignancies PALO ALTO, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commerci
PALO ALTO, Calif., Oct. 25, 2021 /PRNewswire/ -- BridgeBio Pharma, Inc. (NASDAQ:BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it has added a new independent director to its board: Hannah Valantine, M.D., a national leader in organ transplant genomics who led the National Institutes of Health's efforts to promote diversity, equity, and inclusion in biomedical research. Dr. Valantine currently serves as a professor of medicine at Stanford University School of Medicine, where she has been a faculty member since 1987. Dr. Valantine was elected to the National Academy of Medicine in 2020 for her research in organ transplantation